Redmile Group, LLC Neurocrine Biosciences Inc Transaction History

Redmile Group, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $237,832 - $324,881	-2,740 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $197,937 - $250,079	2,740 New	2,740 $231,000
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $388,639 - $515,197	-6,640 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $318,520 - $406,899	6,640	6,640 $407,000

634

94.1M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.